BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Oct 4, 2017
Preclinical News

Team ties target to GBM progression, identifies biomarker

In a paper published in Cancer Cell , researchers at Massachusetts Institute of Technology and Harvard Medical School used an in vivo short hairpin RNA screen to identify an epigenetic regulator, protein arginine methyltransferase 5 (PRMT5)...
BioCentury | Apr 21, 2016
Distillery Therapeutics

Therapeutics: Methionine adenosyltransferase 2A (MAT2A); protein arginine methyltransferase 5 (PRMT5); RIO kinase 1 (RIOK1); methylthioadenosine phosphorylase (

Cancer INDICATION: Colorectal cancer Cell culture and mouse studies suggest inhibiting the MAT2A / PRMT5 / RIOK1 axis could help treat MTAP-deficient colon cancer. In a human MTAP-deficient colon cancer cell line, shRNA targeting MAT2A,...
BioCentury | Dec 11, 2008
Distillery Therapeutics

This week in therapeutics

The Distillery: Therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer p21 protein (Cdc42/Rac)-activated kinase 4 (PAK4); RIO kinase 3 (yeast) (RIOK3) Studies in mice and in cell culture suggest that...
Items per page:
1 - 4 of 4